This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a prospective randomised controlled trial, carried out in two centres. The duration of follow up was 28 days. The overall loss to follow up was 24% (18 patients representing 18 episodes of CAP), the distribution by treatment group being as follows; group 1, 25.9% (7/27); group 2, 28.5% (8/28); and group 3, 15% (3/20).
Analysis of effectiveness
The analysis of effectiveness was based on treatment completers only. The health outcome used was 'treatment success', defined as CAP resolved, with resolution of fever and leukocytosis by day 28. Therapeutic failure was, therefore, determined whenever the persistence of fever or leukocytosis, by day 28, required additional antibiotic therapy or a readmission to the hospital for the same infection. Groups were shown to be comparable with respect to age, sex, smoking history, maximum temperature at hospital admission, number of patients with fever, creatinine, WBC count, the number with WBC count elevation, the number of lobes involved, and the presence of a pleural effusion. All of these measures were reported as having differences with p>0.05.
Effectiveness results
The rates of therapeutic success were reported as follows: Group 1, 90%; group 2, 85%; group 3, 94%. The differences were reported as having p>0.05 (the authors reported that "the confidence limits for the hypothesis that there was no significant difference between the 2-day (group 1) versus the combined 5-and 10-day antibiotic treatment groups were -16% (lower) and 17% (upper)".
Clinical conclusions
A course of IV antibiotic therapy for the treatment of CAP "can be shortened without compromising a satisfactory clinical outcome".
Measure of benefits used in the economic analysis
The main benefit measure was'treatment success'.
Direct costs
Quantities were not reported separately. The cost itemsmeasured were not clearly reported. The authors only reported that "the cost per day (overall estimate of cost) includes all direct and indirect costs of patient care. Indirect costs include overhead hospital and labor costs". The estimation of quantities was only related to length of hospital stay (LOS). The boundary adopted was the hospital. The cost per day estimate was based on the 1994 "cost per day of acute medical ward admissions at the Bronx VAMC and nationally in the Department of Veterans Affairs (DVA)". The LOS measurement for the study group was based on study measurements, which were carried out between September 1993 and March 1995.
